mFluiDX
Enabling molecular detection anywhere
mFluiDX is active in the diagnostics space based in United States, founded in 2016.
Profile
The mFluiDx platform is fully autonomous, smart-phone enabled unit ideal for on-site testing. Also, Injection molding allows mass production of chips at cost 1000 times lower than PCR. In addition, sothermal nucleic acid amplification allows sensitivity comparable to PCR. So, with quick and accurate results the platform allows real-time tracking of outbreak, conveying important information during most crucial times of outbreak.
mFluiDX is positioned in diagnostics, a segment that rewards a clear, focused offering.
The business is associated with United States.
The company is listed at the SOSV portfolio company stage of development.
| Sector | Diagnostics |
|---|---|
| Country | United States |
| Founded | 2016 |
| Stage | SOSV portfolio company |
Website: mfluidx.com
Create a free account